Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Qiagen GeneGlobe

Premium

Qiagen this week announced new capabilities for GeneGlobe, a web-based solution enabling researchers to search and select from more than 31 million PCR assay kits and next-generation sequencing assay panel products.

The new version of GeneGlobe integrates biological knowledge from the Ingenuity Target Explorer bioinformatics application with GeneGlobe's extensive library of wet lab assay solutions. By linking biological interpretation and references with the relevant laboratory assays, GeneGlobe creates a new dimension of utility for experimental design, assay selection, and data analysis, Qiagen said.

GeneGlobe includes genome-wide assay solutions for 28 species with any gene or pathway of interest. The search, selection, and interpretation features precisely identify assays and reagents that fit a life science researcher's experimental design and add a comprehensive set of interpretation solutions. GeneGlobe also features resources such as Pathway Central, Data Analysis Center, Custom Assay Design Tools, and the Plate Designer.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.